1239358-99-6

Basic information

• Product Name: (S)-2-{2-[1-(4-fluorophenyl)ethyl]-6-(pyrazin-2-ylamino)pyridin-4-yloxy}ethanol
• Synonyms: (S)-2-{2-[1-(4-fluorophenyl)ethyl]-6-(pyrazin-2-ylamino)pyridin-4-yloxy}ethanol
• CAS NO: 1239358-99-6
• Molecular Weight: 369.399
• Mol File: 1239358-99-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (S)-2-{2-[1-(4-fluorophenyl)ethyl]-6-(pyrazin-2-ylamino)pyridin-4-yloxy}ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-{2-[1-(4-fluorophenyl)ethyl]-6-(pyrazin-2-ylamino)pyridin-4-yloxy}ethanol(1239358-99-6)
• EPA Substance Registry System: (S)-2-{2-[1-(4-fluorophenyl)ethyl]-6-(pyrazin-2-ylamino)pyridin-4-yloxy}ethanol(1239358-99-6)

Safety Data

• Hazardous Substances Data: 1239358-99-6(Hazardous Substances Data)

Upstream product

• 1354800-11-5 (S)-4,6-dichloro-N-[1-(4-fluorophenyl)ethyl]pyridin-2-amine 
• 66399-30-2 (S)-1-(4-Fluoro-phenyl)-ethylamine 
• 16063-69-7 2,4,6-trichloropyridine 
• 1354807-11-6 (S)-4-chloro-N₂-[1-(4-fluorophenyl)ethyl]-N₆-(pyrazin-2-yl)pyridine-2,6-diamine 
• 107-21-1 ethylene glycol 

Relevant articles and documents

Therapeutic agent pcnsl (by machine translation)

The present invention provides a malignant lymphoma therapeutic or preventive agent that comprises as the active ingredient a compound represented by general formula [1] as defined by (I) or (II), or a pharmaceutically acceptable salt thereof. [1] (I) X is CH or N; R1 is a halogen; R2 is a halogen, H, a cyano, a group represented by general formula [9], [9] an optionally substituted heteroaryl, or the like; R3 is H or a hydroxyl; R4 is H or an alkyl; and R5 is H or an alkyl. (II) X is -CRA, RA is -CORB, RB is an optionally substituted amino, alkoxy, or saturated cyclic amino group; R1 is a halogen; R2 is H; R3is H or a hydroxy; R4 is H or an alkyl; and R5 is H or an alkyl.